Compare Amphastar Pharmaceuticals Inc (AMPH) vs Palantir Technologies Inc (PLTR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

PLTR trades at $126.79, down 1.74% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong fundamentals, with Q1 2026 EPS of $0.33 beating expectations, revenue growth accelerating to 85% YoY, and a net income margin of 43.67%. Recent news highlights CEO commentary on AI competition and robust U.S. revenue expansion of 104%.

The outlook remains positive given earnings beats and growth trajectory, but high valuation multiples (P/E 142.46) pose a risk if growth slows. Analyst consensus price target is $185.67, suggesting upside, though bearish technicals and sector volatility warrant caution for near-term entry.